NR3C2 and diabetic kidney disease: The steroidal mineralocorticoid receptor antagonist (MRA) spironolactone has been shown to attenuate albuminuria in diabetic kidney disease without outcomes data but had numerous disadvantages including sexual side effects and significant hyperkalemia that can be prolonged for as long as 1 week after discontinuation as a result of long-acting metabolites such as canrenone [89, 90].